Additional file 2 of Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis

Additional file 2: Fig. S1. Forest plot of pooled seropositive rate difference between third and second dose in HSCT patients. Fig. S2. Forest plot of pooled seropositive rate difference between fourth and third dose in HSCT patients. Fig. S3. Forest plot of pooled seropositive rate difference between third and second dose in CAR-T cell patients. Fig. S4. Forest plot of seroconversion after the third dose in HSCT recipients by the interval between transplantation and vaccination initiation. This plot demonstrates higher seroconversion rates among patients with a median interval of more than 12 months from cell therapy to the first dose of immunization. Fig. S5. Forest plot of seroconversion after third dose in HSCT recipients by brand of the mRNA vaccine received.

附加文件2：补充图S1. 造血干细胞移植（HSCT）患者第三剂与第二剂疫苗间合并血清阳性率差异的森林图。补充图S2. 造血干细胞移植（HSCT）患者第四剂与第三剂疫苗间合并血清阳性率差异的森林图。补充图S3. 嵌合抗原受体T细胞（CAR-T）患者第三剂与第二剂疫苗间合并血清阳性率差异的森林图。补充图S4. 按移植至疫苗接种起始时间间隔分组的造血干细胞移植（HSCT）受者第三剂疫苗接种后血清转换率的森林图。该图显示，从细胞治疗至首剂免疫接种的中位间隔超过12个月的患者，其血清转换率更高。补充图S5. 按接种的信使核糖核酸（mRNA）疫苗品牌分组的造血干细胞移植（HSCT）受者第三剂疫苗接种后血清转换率的森林图。